<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:ali="http://www.niso.org/schemas/ali/1.0" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Iran J Pediatr</journal-id><journal-id journal-id-type="iso-abbrev">Iran J Pediatr</journal-id><journal-id journal-id-type="doi">10.5812/ijp</journal-id><journal-id journal-id-type="publisher-id">Kowsar</journal-id><journal-title-group><journal-title>Iranian Journal of Pediatrics</journal-title></journal-title-group><issn pub-type="ppub">2008-2142</issn><issn pub-type="epub">2008-2150</issn><publisher><publisher-name>Kowsar</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">26199710</article-id><article-id pub-id-type="pmc">4505992</article-id><article-id pub-id-type="doi">10.5812/ijp.25(3)2015.494</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Efficacy and Safety of Orally Administered Intravenous Midazolam Versus a Commercially Prepared Syrup</article-title></title-group><contrib-group><contrib id="idm22457984" contrib-type="author"><name><surname>Salem</surname><given-names>Katayoun</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="corresp" rid="idp105936">*</xref></contrib><contrib id="idm22455312" contrib-type="author"><name><surname>Khoshrang</surname><given-names>Hossein</given-names></name><xref ref-type="aff" rid="aff2">2</xref></contrib><contrib id="idm22454544" contrib-type="author"><name><surname>Kousha</surname><given-names>Maryam</given-names></name><xref ref-type="aff" rid="aff3">3</xref></contrib><contrib id="idm22453904" contrib-type="author"><name><surname>Hoseini</surname><given-names>Mahboobeh</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="idm22453264" contrib-type="author"><name><surname>Ranjbar</surname><given-names>Marzieh</given-names></name><xref ref-type="aff" rid="aff1">1</xref></contrib><contrib id="idm22452624" contrib-type="author"><name><surname>Baniasadi</surname><given-names>Shadi</given-names></name><xref ref-type="aff" rid="aff4">4</xref></contrib><contrib id="idm22448784" contrib-type="author"><name><surname>Salamzadeh</surname><given-names>Jamshid</given-names></name><xref ref-type="aff" rid="aff5">5</xref></contrib></contrib-group><aff id="aff1"><label>1</label>Department of Pediatric Dentistry and Dentistry Hospital, Guilan Dental School, Rasht, IR Iran
</aff><aff id="aff2"><label>2</label>Department of Anesthesiology, Guilan University of Medical Sciences, Rasht, IR Iran</aff><aff id="aff3"><label>3</label>Department of Child Psychiatry, Guilan University of Medical Sciences, Rasht, IR Iran</aff><aff id="aff4"><label>4</label>Masih Daneshvari Hospital, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran</aff><aff id="aff5"><label>5</label>Deparment of Clinical Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran</aff><author-notes><corresp id="idp105936"><label>*</label>Corresponding author: Katayoun Salem, Department of Pediatric Dentistry and Hospital Dentistry, Guilan Dental School, Rasht, IR Iran. E-mail: <email>katayoun.salem@gmail.com</email></corresp></author-notes><pub-date pub-type="epub"><day>27</day><month>6</month><year>2015</year></pub-date><pub-date pub-type="ppub"><month>6</month><year>2015</year></pub-date><volume>25</volume><issue>3</issue><elocation-id>e494</elocation-id><history><date date-type="received"><day>24</day><month>12</month><year>2013</year></date><date date-type="accepted"><day>26</day><month>9</month><year>2014</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2015, Growth &#x00026; Development Research Center.</copyright-statement><copyright-year>2015</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/"><license-p><!--CREATIVE COMMONS-->This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by-nc/4.0/">http://creativecommons.org/licenses/by-nc/4.0/</ext-link>) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.</license-p></license></permissions><abstract><sec><title>Background:</title><p>Among different categories of sedative agents, benzodiazepines have been prescribed for more than three decades to patients of all ages. The effective and predictable sedative and amnestic effects of benzodiazepines support their use in pediatric patients. Midazolam is one of the most extensively used benzodiazepines in this age group. Oral form of drug is the best accepted route of administration in children.</p></sec><sec><title>Objectives:</title><p>The purpose of this study was to compare the efficacy and safety of a commercially midazolam syrup versus orally administered IV midazolam in uncooperative dental patients. Second objective was to determine whether differences concerning sedation success can be explained by child&#x02018;s behavioral problems and dental fear.</p></sec><sec><title>Patients and Methods:</title><p>Eighty eight uncooperative dental patients (Frankl Scales 1,2) aged 3 to 6 years, and ASA I participated in this double blind, parallel randomized, controlled clinical trial. Midazolam was administered in a dose of 0.5 mg/kg for children under the age 5 and 0.2 mg/kg in patients over 5 years of age. Physiologic parameters including heart rate, respiratory rate, oxygen saturation and blood pressure were recorded. Behavior assessment was conducted throughout the course of treatment using Houpt Sedation Rating Scale and at critical moments of treatment (injection and cavity preparation) by North Carolina Scale. Dental fear and behavioral problems were evaluated using Child Fear Schedule Survey-Dental Subscale (CFSS-DS), and Strength and Difficulties Questionnaire (SDQ). Independent t-test, Chi-Square, and Pearson correlation were used for statistical analysis.</p></sec><sec><title>Results:</title><p>Acceptable overall sedation ratings were observed in 90% and 86% of syrup and IV/Oral group respectively; Chi-Square P = 0.5. Other domains of Houpt Scale including: sleep, crying and movement were also not significantly different between groups. Physiological parameters remained in normal limits during study without significant difference between groups.</p></sec><sec><title>Conclusions:</title><p>&#x0201c;Orally administered IV midazolam&#x0201d; preparation can be used as an alternative for commercially midazolam syrup.</p></sec></abstract><kwd-group kwd-group-type="author"><kwd>Sedation</kwd><kwd>Uncooperative Patient</kwd><kwd>Oral Midazolam</kwd><kwd>Clinical Trial</kwd><kwd>Child</kwd></kwd-group></article-meta></front><body><sec><title>1. Background</title><p>Despite substantial improvements in modern pediatric dentistry, a number of children cannot cope with dental treatment by behavior guidance techniques. In these patients pharmacological intervention may be advocated (<xref rid="A494REF1" ref-type="bibr">1</xref>, <xref rid="A494REF2" ref-type="bibr">2</xref>) to replace the previous experiments with a different new treatment approach that is known as retraining process (<xref rid="A494REF3" ref-type="bibr">3</xref>). Among different categories of sedative agents, benzodiazepines have been prescribed for more than three decades to patients of all ages. The effective and predictable sedative and amnestic effects of benzodiazepines support their use in pediatric patients. Midazolam is one of the most extensively used benzodiazepines in this age group. Oral form of drug is the best accepted route of administration in children (<xref rid="A494REF3" ref-type="bibr">3</xref>-<xref rid="A494REF7" ref-type="bibr">7</xref>). However commercially prepared midazolam syrup is not available in some countries. In addition the cost of the drug is relatively high, that is another concern in daily practice. As an alternative a mixture of IV injectable midazolam and a flavoring agent has been used (<xref rid="A494REF8" ref-type="bibr">8</xref>). The flavoring vehicle is used to mask the bitter taste and to adjust the pH of the drug (<xref rid="A494REF9" ref-type="bibr">9</xref>, <xref rid="A494REF10" ref-type="bibr">10</xref>), that is an important consideration in drug absorption (<xref rid="A494REF11" ref-type="bibr">11</xref>). Since the midazolam syrup is not accessible in our country, and due to lack of similar studies, the main objective of this investigation was to compare the efficacy and safety of an extemporaneous form of drug that is prepared by pharmacist (orally administered IV midazolam) and a commercially midazolam syrup. </p><p>In addition, it is shown that not every child benefits from midazolam sedation. There are a variety of factors other than the type of sedative and its dose that involve in effectiveness of midazolam. The effects of child&#x02019;s temperament and behavioral problem on midazolam effectiveness are not investigated extensively. Fear/anxiety and behavioral problems (<xref rid="A494REF2" ref-type="bibr">2</xref>, <xref rid="A494REF12" ref-type="bibr">12</xref>), and high levels of impulsivity (<xref rid="A494REF13" ref-type="bibr">13</xref>) and emotionality (<xref rid="A494REF14" ref-type="bibr">14</xref>) are among factors that may contraindicate midazolam premedication in children. Determining those children who do not benefit from sedation is important to clinicians like pediatric dentists who encounter uncooperative children in a daily basis. </p></sec><sec><title>2. Objectives</title><p>The main objective of this investigation was to compare the efficacy and safety of an extemporaneous form of drug that is prepared by pharmacist (orally administered I.V midazolam) and a commercially midazolam syrup. As an adjunct objective the present study investigated whether differences concerning sedation success can be explained by child&#x02019;s behavioral problems and dental fear.
</p></sec><sec><title>3. Patients and Methods</title><sec><title>3.1. Samples</title><p>After gaining written parental consent, eighty eight uncooperative pediatric patients aged 3 to 6 years, who were referred to Pediatric Clinic of Guilan Dental School for uncooperative behavior participated in this double blind and randomized controlled clinical trial. The study had a two arm parallel design. Patients were randomly assigned to either midazolam syrup group or &#x0201c;orally administered IV midazolam&#x0201d; group via 6 quadric blocks. Sample size was calculated using a previous sedation study (<xref rid="A494REF8" ref-type="bibr">8</xref>). Power was set at 80%, &#x003b1; = 0.05 and a 25% clinical difference between groups was estimated for sample size determination. All children were healthy (ASA class I) and rated as class 1 or 2 on the Frankl Behavioral Rating Scale, which means negative or definitely negative behavior (<xref rid="A494REF3" ref-type="bibr">3</xref>). Patients were excluded from the study in the case of physical or mental disabilities, history of common cold in the past two weeks, Tonsil/adenoid hypertrophy (Brodsky tonsil score &#x0003e; 2), or any anatomical deformities in face and neck such as micrognathia and macroglossia.</p></sec><sec><title>3.2. Drug Regimen</title><p>Regimen A: Midazolam Maleate syrup sugar free liquid (Amsed 2.5 mg/mL UK). Commercially available syrup (Amsed, UK) included sugar free midazolam maleate syrup and was prepared in pH 4.</p><p>Regimen B: Orally administered IV midazolam 2.5 mg/mL that consisted of the injectable solution of midazolam hydrochloride (Amp. 15 mg/3 mL Midamax, Tehran Chimi, Iran,), in combination with Syrup BP (66.7% sucrose, 33.3% water as solvent) and orange extract flavoring. The compound was prepared in pH 3.5 by the responsible pharmacist with shelf life of 14 days. Adjustment to a pH of about 3.5 ensured that the drug stays stable in solution (<xref rid="A494REF14" ref-type="bibr">14</xref>, <xref rid="A494REF15" ref-type="bibr">15</xref>).</p><p>Drugs were calculated by responsible researcher and administrated by dental nurse who was unaware of the study design, using a needleless syringe in the dose of 0.2 or 0.5 mg/kg. A dose of 0.2 mg/kg was administered to children over age five years and in patients less than five years of age 0.5 mg/kg was prescribed (<xref rid="A494REF16" ref-type="bibr">16</xref>). The midazolam dose is routinely individualized based on patient's age (older children need less of drug), degree of anxiety, and the level of sedation desired (<xref rid="A494REF6" ref-type="bibr">6</xref>). After administration of medication the child was kept under supervision for 30 minutes and then transferred to dental chair and dental treatment began. Parents were not present during dental treatment session. The dental appointment included injection and restorative/pulp treatment and did not exceed 30 minutes. All treatments were provided by a pediatric dentist who was unaware of drug regimen.</p></sec><sec><title>3.3. Efficacy</title><p>Sedation efficacy was rated by an examiner who was blind to the sedative regimen. Two separate criteria were used to assess sedation success: &#x0201c;North Carolina Behavior Rating Scale&#x0201d; (NC) (<xref ref-type="table" rid="A494TBL1">Table 1</xref>) and &#x0201c;Houpt Sedation Rating Scale&#x0201d; (<xref ref-type="table" rid="A494TBL2">Table 2</xref>) (<xref rid="A494REF17" ref-type="bibr">17</xref>). The NC (<xref rid="A494REF18" ref-type="bibr">18</xref>) was used to evaluate the child&#x02019;s behavior at the moment of local anesthesia injection, and at cavity preparation. The other evaluation criterion &#x0201c;Houpt Sedation Rating Scale&#x0201d; (<xref rid="A494REF17" ref-type="bibr">17</xref>) divides the sedation status to four subdomains of sleep, movement, crying and overall behavior (<xref ref-type="table" rid="A494TBL2">Table 2</xref>). </p><table-wrap id="A494TBL1" orientation="portrait" position="float"><label>Table 1.</label><caption><title>Definition of North Carolina Behavior Rating Scale <sup><xref ref-type="table-fn" rid="A494TBL1FN1">a</xref></sup></title></caption><table frame="hsides" rules="groups"><thead><tr><th style="text-align: left;" rowspan="1" colspan="1">Behavior</th><th rowspan="1" colspan="1">Definition</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<bold>Quiet</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">Patient is quiet or sleeping with only extraneous, inconsequential movements</td></tr><tr><td rowspan="1" colspan="1">
<bold>Annoyed</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">Patient is cooperative for treatment but with 1 or 2 undesirable behaviors</td></tr><tr><td rowspan="1" colspan="1">
<bold>Upset</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">Patient noticeably disturbed, with 2 to 3 undesirable behaviors <sup><xref ref-type="table-fn" rid="A494TBL1FN2">b</xref></sup> present making treatment difficult</td></tr><tr><td rowspan="1" colspan="1">
<bold>Wild</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">Patient extremely defiant with presence of all undesirable behaviors <sup><xref ref-type="table-fn" rid="A494TBL1FN2">b</xref></sup> making treatment extremely difficult</td></tr></tbody></table><table-wrap-foot><fn id="A494TBL1FN1"><p><sup>a</sup>References No. (<xref rid="A494REF18" ref-type="bibr">18</xref>, <xref rid="A494REF19" ref-type="bibr">19</xref>).</p></fn><fn id="A494TBL1FN2"><p><sup>b</sup> Undesirable behavior includes: crying, screaming, head movement, torso movement, or foot movement.</p></fn></table-wrap-foot></table-wrap><table-wrap id="A494TBL2" orientation="portrait" position="float"><label>Table 2.</label><caption><title>Definition of Houpt Sedation Rating Scale <sup><xref ref-type="table-fn" rid="A494TBL2FN1">a</xref></sup></title></caption><table frame="hsides" rules="groups"><thead><tr><th style="text-align: left;" rowspan="1" colspan="1">Rating Scale</th><th rowspan="1" colspan="1">Definition</th><th rowspan="1" colspan="1">Score</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<bold>Rating Scale for Sleep</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">Fully awake, alert</td><td style="text-align: center;" rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1">Drowsy, disoriented</td><td style="text-align: center;" rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1">Asleep</td><td style="text-align: center;" rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1">
<bold>Rating Scale for Movement</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">Violent movement that interrupts treatment</td><td style="text-align: center;" rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1">Continuous movement that makes treatment difficult</td><td style="text-align: center;" rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1">Controllable movement that does not interfere with treatment</td><td style="text-align: center;" rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1">No movement</td><td style="text-align: center;" rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">
<bold>Rating Scale for Crying</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">Hysterical crying that interrupts treatment</td><td style="text-align: center;" rowspan="1" colspan="1">1</td></tr><tr><td rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1">Continuous, persistent crying that makes treatment difficult</td><td style="text-align: center;" rowspan="1" colspan="1">2</td></tr><tr><td rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1">Intermittent, mild crying that does not interfere with treatment</td><td style="text-align: center;" rowspan="1" colspan="1">3</td></tr><tr><td rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1">No crying</td><td style="text-align: center;" rowspan="1" colspan="1">4</td></tr><tr><td rowspan="1" colspan="1">
<bold>Rating Scale for Overall Behavior</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Aborted</td><td style="text-align: center;" rowspan="1" colspan="1">No treatment</td><td style="text-align: center;" rowspan="1" colspan="1">1</td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Poor</td><td style="text-align: center;" rowspan="1" colspan="1">Treatment interrupted, only partial treatment completed</td><td style="text-align: center;" rowspan="1" colspan="1">2</td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Fair</td><td style="text-align: center;" rowspan="1" colspan="1">Treatment interrupted but eventually all completed</td><td style="text-align: center;" rowspan="1" colspan="1">3</td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Good</td><td style="text-align: center;" rowspan="1" colspan="1">Difficult, but all treatment performed</td><td style="text-align: center;" rowspan="1" colspan="1">4</td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Very good</td><td style="text-align: center;" rowspan="1" colspan="1">Some limited crying or movement, e.g. during anesthesia or mouth prop</td><td style="text-align: center;" rowspan="1" colspan="1">5</td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Excellent</td><td style="text-align: center;" rowspan="1" colspan="1">No crying or movement</td><td style="text-align: center;" rowspan="1" colspan="1">6</td></tr></tbody></table><table-wrap-foot><fn id="A494TBL2FN1"><p><sup>a</sup>References No. (<xref rid="A494REF17" ref-type="bibr">17</xref>)</p></fn></table-wrap-foot></table-wrap></sec><sec><title>3.4. Safety</title><p>Safety of the two sedative regimens was evaluated by physiological parameters including Heart Rate (HR), Respiratory Rate (RR), oxygen saturation (SpO<sub>2</sub>) and blood pressure (BP). All the patients were monitored using a pulse oximeter (SANOFI A 320, China) and digital blood pressure device. Oxygen saturation was constantly monitored. Hypoxemia was determined as SpO<sub>2</sub> less than 93% (<xref rid="A494REF8" ref-type="bibr">8</xref>). Physiological parameters were rated before sedation as baseline measure, and then at the beginning of treatment and every 15 minutes until the end of treatment.</p></sec><sec><title>3.5. Behavior Problems and Dental Fear</title><p>The second objective of the present study was to determine the success rate of sedation in children with and without behavior problems among study population. An assessment of child&#x02019;s behavioral problems, was conducted using the &#x0201c;Strengths and Difficulties Questionnaire (SDQ)&#x0201d; (<xref rid="A494REF20" ref-type="bibr">20</xref>). The SDQ is a brief mental health questionnaire for children and adolescents. It can screen the behavioral problems (by total difficulty score) and the emotional sub-scale can show the general anxiety of the children. The 25 SDQ items are divided into five scales. These scales are SDQ 1/conduct problems, SDQ 2/hyperactivity-inattention, SDQ 3/emotional symptoms, SDQ 4/peer problems and SDQ 5/pro-social behaviors.</p><p>The mentioned scales scores (except the last one) are added up to generate a total score. The reliability and validity of Persian version of questionnaire has shown in Iranian population by Tehranidoost et al. (<xref rid="A494REF20" ref-type="bibr">20</xref>). Scoring and interpretation of scores were done by the institution of cognitive sciences.</p><p>As the other measure we assessed the level of child&#x02019;s dental fear; to determine the sedation success in children with and without dental fear using Child Fear Survey Schedule-Dental Subscale (CFSS-DS) questionnaire. This Likert type questionnaire includes 15 questions to be completed by parents. The patients score can be placed in the range of 15 - 75 and &#x0003e; 38 is considered as dental fear (<xref rid="A494REF21" ref-type="bibr">21</xref>). Data were statistically analyzed using the Independent t-test and Chi-Square test. Significance level was established at P &#x0003c; 0.05 in SPSS16 software environment.</p></sec></sec><sec><title>4. Results</title><p>A total of eighty eight children participated in the study (45.5% males and 54.5% females). The mean age of patients in group A (midazolam syrup) and B (orally administered IV midazolam) was 72.2 &#x000b1; 11.9 and 68 &#x000b1; 12.4 months respectively. The mean weight of children was 20.2 &#x000b1; 5.4 and 18.4 &#x000b1; 3.9 kg in groups A and B respectively. There were no statistical differences in gender, age and weight between the two groups. The flow diagram of the participants is presented in <xref ref-type="fig" rid="A494FIG1">Figure 1</xref>.</p><fig id="A494FIG1" fig-type="inline" orientation="portrait" position="float"><label>Figure 1.</label><caption><title>Consort Flow Diagram of Study Groups</title></caption><ext-link ext-link-type="uri" xlink:href="http://cdn.neoscriber.org/cdn/serve/c3/b0/c3b0019dfe305189130a6f848b2a444cdbabc90e/ijp-25-494-i001.eps"/><graphic xlink:href="ijp-25-494-i001"/></fig><sec><title>4.1. Sedation Assessment</title><p>Behavior at the time of injection and cavity preparation (North Carolina scale): Ratings of North Carolina scale are summarized in <xref ref-type="table" rid="A494TBL3">Table 3</xref>. The participants of the two groups did not show significant difference in their behavior during injection and cavity preparation. Quiet and annoyed behaviors were the most observed behaviors. Wild behavior was the least observed behavior in both groups.</p><table-wrap id="A494TBL3" orientation="portrait" position="float"><label>Table 3.</label><caption><title>Frequency of Exhibited Behavior During Sedation by North Carolina Behavior Rating Scale <sup>a</sup></title></caption><table frame="hsides" rules="groups"><thead><tr><th style="text-align: left;" rowspan="1" colspan="1">Group</th><th rowspan="1" colspan="1">Quiet</th><th rowspan="1" colspan="1">Annoyed</th><th rowspan="1" colspan="1">Upset</th><th rowspan="1" colspan="1">Wild</th><th rowspan="1" colspan="1">P Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<bold>Injection</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1">0.5</td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">A</td><td style="text-align: center;" rowspan="1" colspan="1">17 (38.6)</td><td style="text-align: center;" rowspan="1" colspan="1">20 (45.5)</td><td style="text-align: center;" rowspan="1" colspan="1">7 (15.9)</td><td style="text-align: center;" rowspan="1" colspan="1">0 (0)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">B</td><td style="text-align: center;" rowspan="1" colspan="1">19 (43.2)</td><td style="text-align: center;" rowspan="1" colspan="1">17 (38.6)</td><td style="text-align: center;" rowspan="1" colspan="1">6 (13.6)</td><td style="text-align: center;" rowspan="1" colspan="1">2 (4.5)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>Cavity prep</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1">0.4</td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">A</td><td style="text-align: center;" rowspan="1" colspan="1">24 (54.5)</td><td style="text-align: center;" rowspan="1" colspan="1">14 (31.8)</td><td style="text-align: center;" rowspan="1" colspan="1">6 (13.6)</td><td style="text-align: center;" rowspan="1" colspan="1">0 (0)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">B</td><td style="text-align: center;" rowspan="1" colspan="1">19 (43.2)</td><td style="text-align: center;" rowspan="1" colspan="1">17 (38.6)</td><td style="text-align: center;" rowspan="1" colspan="1">6 (13.6)</td><td style="text-align: center;" rowspan="1" colspan="1">2 (4.5)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="A494TBL3FN1"><p><sup>a</sup> Abbreviations: A: Commercial available syrup, B: Orally administered injectable midazolam.</p></fn></table-wrap-foot></table-wrap><p>Level of sleep, crying, movement and overall behavior (Houpt): Houpt Behavior Rating Scale was used to determine level of sleep, crying, movement and overall child&#x02019;s behavior during each sedation appointment (<xref ref-type="table" rid="A494TBL4">Table 4</xref>). There was not significantly different between groups. In both groups almost all patients were alert/drowsy. Hysterical crying, violent movement and aborted treatment was observed in one case in group B.</p><table-wrap id="A494TBL4" orientation="portrait" position="float"><label>Table 4.</label><caption><title>Houpt Sedation Rating Scale in the Two Groups</title></caption><table frame="hsides" rules="groups"><thead><tr><th style="text-align: left;" rowspan="1" colspan="1">Domain</th><th rowspan="1" colspan="1">A <sup><xref ref-type="table-fn" rid="A494TBL4FN1">a</xref></sup></th><th rowspan="1" colspan="1">B <sup><xref ref-type="table-fn" rid="A494TBL4FN1">a</xref></sup></th><th rowspan="1" colspan="1">P Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><bold>Sleep</bold></td><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1">0.2</td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Alert</td><td style="text-align: center;" rowspan="1" colspan="1">20 (45.5)</td><td style="text-align: center;" rowspan="1" colspan="1">26 (59.1)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Drowsy</td><td style="text-align: center;" rowspan="1" colspan="1">22 (50)</td><td style="text-align: center;" rowspan="1" colspan="1">18 (40.9)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Asleep</td><td style="text-align: center;" rowspan="1" colspan="1">2 (4.5)</td><td style="text-align: center;" rowspan="1" colspan="1">0 (0)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>Crying</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1">0.6</td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Hysterical </td><td style="text-align: center;" rowspan="1" colspan="1">0 (0)</td><td style="text-align: center;" rowspan="1" colspan="1">1 (2.3)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Continuous</td><td style="text-align: center;" rowspan="1" colspan="1">7 (15.9)</td><td style="text-align: center;" rowspan="1" colspan="1">8 (18.2)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Intermittent</td><td style="text-align: center;" rowspan="1" colspan="1">17 (38.6)</td><td style="text-align: center;" rowspan="1" colspan="1">19 (43.2)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">No crying</td><td style="text-align: center;" rowspan="1" colspan="1">20 (45.5)</td><td style="text-align: center;" rowspan="1" colspan="1">16 (36.4)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>Movement</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1">0.6</td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Violent</td><td style="text-align: center;" rowspan="1" colspan="1">0 (0)</td><td style="text-align: center;" rowspan="1" colspan="1">1 (2.3)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Continuous</td><td style="text-align: center;" rowspan="1" colspan="1">11 (25)</td><td style="text-align: center;" rowspan="1" colspan="1">10 (22.7)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Controllable</td><td style="text-align: center;" rowspan="1" colspan="1">12 (27.3)</td><td style="text-align: center;" rowspan="1" colspan="1">15 (34.1)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">No movement</td><td style="text-align: center;" rowspan="1" colspan="1">21 (47.7)</td><td style="text-align: center;" rowspan="1" colspan="1">18 (40.9)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>Overall Behavior</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1">0.6</td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Aborted</td><td style="text-align: center;" rowspan="1" colspan="1">0 (0)</td><td style="text-align: center;" rowspan="1" colspan="1">1 (2.3)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Poor</td><td style="text-align: center;" rowspan="1" colspan="1">1 (2.3)</td><td style="text-align: center;" rowspan="1" colspan="1">0 (0)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Fair</td><td style="text-align: center;" rowspan="1" colspan="1">3 (6.8)</td><td style="text-align: center;" rowspan="1" colspan="1">5 (11.4)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Good</td><td style="text-align: center;" rowspan="1" colspan="1">8 (18.2)</td><td style="text-align: center;" rowspan="1" colspan="1">7 (15.9)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Very good</td><td style="text-align: center;" rowspan="1" colspan="1">19 (43.2)</td><td style="text-align: center;" rowspan="1" colspan="1">22 (50)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Excellent</td><td style="text-align: center;" rowspan="1" colspan="1">13 (29.5)</td><td style="text-align: center;" rowspan="1" colspan="1">9 (20.5)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Total</td><td style="text-align: center;" rowspan="1" colspan="1">44 (100)</td><td style="text-align: center;" rowspan="1" colspan="1">44 (100)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="A494TBL4FN1"><p><sup>a</sup> Values are presented as No. (%).</p></fn></table-wrap-foot></table-wrap><p>For a better perception of sedation outcome the overall behavior was dichotomized into acceptable (excellent, very good and good) and unacceptable (fair, poor and aborted) behavior. </p><p>The acceptable behavior was observed in 90.9% of patients in group A (CL: 0.85 - 0.96) and in 86.4% of group B (CL: 0.87 - 0.93). The mean age of patients with overall acceptable and unacceptable behavior was compared. There was no significant difference between the mean age of children with each category of behavior (<xref ref-type="table" rid="A494TBL5">Table 5</xref>).</p><table-wrap id="A494TBL5" orientation="portrait" position="float"><label>Table 5.</label><caption><title>Mean Age of Children With Acceptable and Unacceptable Behavior in the Two Groups</title></caption><table frame="hsides" rules="groups"><thead><tr><th style="text-align: left;" rowspan="1" colspan="1">Behavior of Groups</th><th rowspan="1" colspan="1">n</th><th rowspan="1" colspan="1">Mean Age, mo</th><th rowspan="1" colspan="1">P Value</th></tr></thead><tbody><tr><td rowspan="1" colspan="1"><bold>A</bold></td><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Acceptable</td><td style="text-align: center;" rowspan="1" colspan="1">40</td><td style="text-align: center;" rowspan="1" colspan="1">71.6</td><td style="text-align: center;" rowspan="1" colspan="1">0.2</td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Unacceptable</td><td style="text-align: center;" rowspan="1" colspan="1">4</td><td style="text-align: center;" rowspan="1" colspan="1">79.7</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>B</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Acceptable</td><td style="text-align: center;" rowspan="1" colspan="1">38</td><td style="text-align: center;" rowspan="1" colspan="1">68.1</td><td style="text-align: center;" rowspan="1" colspan="1">0.9</td></tr><tr><td style="padding-left: 20pt;" rowspan="1" colspan="1">Unacceptable</td><td style="text-align: center;" rowspan="1" colspan="1">6</td><td style="text-align: center;" rowspan="1" colspan="1">67.8</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr></tbody></table></table-wrap></sec><sec><title>4.2. Physiologic Parameters</title><p>Mean values of physiological parameters (SpO<sub>2</sub>, HR, BP, and RR) are summarized in <xref ref-type="table" rid="A494TBL6">Table 6</xref> and <xref ref-type="fig" rid="A494FIG2">Figure 2</xref> to <xref ref-type="fig" rid="A494FIG4">4</xref>. There were no significant differences in any of physiological parameters during the sedation sessions between the two groups except for SpO<sub>2</sub> level at baseline and at the beginning of treatment that was higher in group A (<xref ref-type="table" rid="A494TBL6">Table 6</xref>). <xref ref-type="fig" rid="A494FIG1">Figures 1</xref> to <xref ref-type="fig" rid="A494FIG3">3</xref> demonstrate the mean values of heart rate, blood pressure and respiratory rate of the two study groups. Serious adverse effects were not observed during and after sedation appointment except for one case of vomiting immediately after drug administration.</p><fig id="A494FIG2" fig-type="inline" orientation="portrait" position="float"><label>Figure 2.</label><caption><title>Mean (SD) Values of Heart Rate Among Syrup (A) Versus &#x0201c;Orally Administered IV Midazolam (B)</title><p>Independent t-test, P &#x0003e; 0.05.</p></caption><ext-link ext-link-type="uri" xlink:href="http://cdn.neoscriber.org/cdn/serve/d4/03/d403b4be5b70e551d9ec3f78bdd77f3dcdae8880/ijp-25-494-i002.eps"/><graphic xlink:href="ijp-25-494-i002"/></fig><fig id="A494FIG3" fig-type="inline" orientation="portrait" position="float"><label>Figure 3.</label><caption><title>Mean (SD) Values of Systolic and Diastolic Blood Pressure in Syrup (A) Versus &#x0201c;Orally Administered IV Midazolam (B)&#x0201d; Groups</title><p>Independent t-test P &#x0003e; 0.05.</p></caption><ext-link ext-link-type="uri" xlink:href="http://cdn.neoscriber.org/cdn/serve/e4/27/e4276fbcd93b79d60096d865ca7cd605021d3056/ijp-25-494-i003.eps"/><graphic xlink:href="ijp-25-494-i003"/></fig><fig id="A494FIG4" fig-type="inline" orientation="portrait" position="float"><label>Figure 4.</label><caption><title>Mean (SD) Values of Respiratory Rate in Syrup (A) Versus &#x0201c;Orally Administered IV Midazolam (B)&#x0201d; Groups</title><p>Independent t-test, P &#x0003e; 0.05.</p></caption><ext-link ext-link-type="uri" xlink:href="http://cdn.neoscriber.org/cdn/serve/d7/b3/d7b33033c82cd63f904a7ac80815be34433f767b/ijp-25-494-i004.eps"/><graphic xlink:href="ijp-25-494-i004"/></fig><table-wrap id="A494TBL6" orientation="portrait" position="float"><label>Table 6.</label><caption><title>Mean Oxygen Saturation Data in Each Group</title></caption><table frame="hsides" rules="groups"><thead><tr><th style="text-align: left;" rowspan="1" colspan="1">SpO<sub>2</sub></th><th rowspan="1" colspan="1">Group <sup><xref ref-type="table-fn" rid="A494TBL6FN1">a</xref></sup></th><th rowspan="1" colspan="1">Mean (SD)</th><th rowspan="1" colspan="1">P Value <sup><xref ref-type="table-fn" rid="A494TBL6FN2">b</xref></sup></th></tr></thead><tbody><tr><td rowspan="1" colspan="1">
<bold>Baseline</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">A</td><td style="text-align: center;" rowspan="1" colspan="1">97.5 (1.7)</td><td style="text-align: center;" rowspan="1" colspan="1">0.02 <sup><xref ref-type="table-fn" rid="A494TBL6FN2">b</xref></sup></td></tr><tr><td rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1">B</td><td style="text-align: center;" rowspan="1" colspan="1">98.2 (1.1)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>Beginning</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">A</td><td style="text-align: center;" rowspan="1" colspan="1">97.1 (2.1)</td><td style="text-align: center;" rowspan="1" colspan="1">0.01 <sup><xref ref-type="table-fn" rid="A494TBL6FN2">b</xref></sup></td></tr><tr><td rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1">B</td><td style="text-align: center;" rowspan="1" colspan="1">98.0 (0.7)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>Minute 15</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">A</td><td style="text-align: center;" rowspan="1" colspan="1">97.5 (1.8)</td><td style="text-align: center;" rowspan="1" colspan="1">0.1</td></tr><tr><td rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1">B</td><td style="text-align: center;" rowspan="1" colspan="1">98.0 (1.3)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr><tr><td rowspan="1" colspan="1">
<bold>Minute 30</bold>
</td><td style="text-align: center;" rowspan="1" colspan="1">A</td><td style="text-align: center;" rowspan="1" colspan="1">97.6 (1.7)</td><td style="text-align: center;" rowspan="1" colspan="1">0.09</td></tr><tr><td rowspan="1" colspan="1"/><td style="text-align: center;" rowspan="1" colspan="1">B</td><td style="text-align: center;" rowspan="1" colspan="1">98.1 (0.7)</td><td style="text-align: center;" rowspan="1" colspan="1"/></tr></tbody></table><table-wrap-foot><fn id="A494TBL6FN1"><p><sup>a</sup> Group A = midazolam syrup; group B = &#x0201c;orally administered IV midazolam&#x0201d;.</p></fn><fn id="A494TBL6FN2"><p><sup>b</sup> Independent t-test. SD: Standard Deviation.</p></fn></table-wrap-foot></table-wrap></sec><sec><title>4.3. Behavior Problems (SDQ) and Dental Fear (CFSS-DS) </title><p>From eighty eight patients 12.6% revealed symptoms of behavioral problems using Strength and Difficulties Questionnaire (SDQ). The distribution of Total SDQ and its subdomains in study population is presented in <xref ref-type="fig" rid="A494FIG5">Figure 5</xref>. There was no significant difference between overall behaviors among three categories of behavioral problems (normal, abnormal, and borderline), Chi-square P = 0.7. From all study population 89.7% of children without signs of behavioral problems, 88.9% of borderlines and 81.8% of behavioral problems demonstrated acceptable behavior during treatment. Dental fear was observed in 50.4% of children. Out of fifty one dentally fearful patients, 84.3% demonstrated acceptable behavior at sedation session. Chi-square test P = 0.1.</p><fig id="A494FIG5" fig-type="inline" orientation="portrait" position="float"><label>Figure 5.</label><caption><title>Distribution of SDQ-Total and Subdomains of SDQ in Study Patients</title></caption><ext-link ext-link-type="uri" xlink:href="http://cdn.neoscriber.org/cdn/serve/43/db/43db7064fc071b967dbaa99496eab82040162365/ijp-25-494-i005.eps"/><graphic xlink:href="ijp-25-494-i005"/></fig></sec></sec><sec><title>5. Discussion</title><p>This double blinded, parallel randomized and controlled trial at first step attempted to evaluate and compare the efficacy and safety of midazolam syrup versus orally administered IV midazolam. Our results demonstrated that both regimens were safe with desirable sedation effects in uncooperative pediatric patients. We did not found any similar study that compares these two formulations; however injectable midazolam-Syrpalta combination showed to be more effective than commercially available syrup by Brosius (<xref rid="A494REF22" ref-type="bibr">22</xref>).</p><p>There are also a number of studies that investigated different doses of &#x0201c;orally administered IV midazolam&#x0201d; with each other or compared it with placebo (<xref rid="A494REF22" ref-type="bibr">22</xref>-<xref rid="A494REF24" ref-type="bibr">24</xref>).</p><p>The safety of preparation was evaluated by physiological parameters. No significant differences were found between the two preparations in any of physiological parameters for the overall sedation time. Although group A had a significantly lower SpO<sub>2</sub> at baseline and at the beginning of treatment, it was over 97% and had no clinical importance. No episodes of desaturation were observed during sedation time except momentary changes during crying. These episodes of decreased SpO<sub>2</sub> never declined under 92%.</p><p>The other physiological parameters remained in normal limit during the sedation appointment. Physiological parameters were not recorded specifically at the times of injection, cavity preparation or crying, however this variable was under the control and monitored continuously to avoid any untoward effect.</p><p>Another consideration in sedation is to determine those children who benefit from midazolam sedation. The results showed that the prevalence of acceptable overall sedation ratings in children with and without symptoms of behavioral problems using SDQ test was similar. However, due to little number of children with behavioral problems these results should be interpreted with caution. Lack of commercially available oral liquid formulations poses a frequent challenge in providing medications for patients with special needs such as pediatric patients, geriatric patients, and patients with feeding tubes to meet the needs of these patients (<xref rid="A494REF25" ref-type="bibr">25</xref>). This study demonstrates promising results by pharmacist-made syrup that will make treatment of uncooperative patients more feasible. Adjusting the pH of product prevents inconsistencies in drug bioavailability. A limitation of this preparation was its short shelf life (14 days); increased stability until 102 days have been reported (<xref rid="A494REF26" ref-type="bibr">26</xref>).</p><p>Under the conditions of this study we conclude that &#x0201c;orally administered IV midazolam&#x0201d; in a dose of 0.2 - 0.5 mg/kg provides safe and effective sedation in 3 to 6 years old uncooperative children. Additionally, our study demonstrated that majority of patients with symptoms of behavioral problems respond to midazolam in an appropriate manner. More research is needed either by increasing the dose or using alternative agents in children with unsuccessful midazolam sedation.</p></sec></body><back><ack><p>The research protocol was reviewed and approved by the Ethical Committee of GUMS, Rasht, Iran. The authors express their appreciation to Deputy of Research of GUMS and Developmental Research center of Guilan Dental School for their support of this project.</p></ack><fn-group><fn fn-type="other" id="afn1"><p><bold>Authors&#x02019; Contributions:</bold>Concept and design: Katayoun Salem and Hossein Khoshrang. Data acquisition: Marzieh Ranjbar and Mahboobeh Hoseini. Manuscript preparation: Katayoun Salem and Maryam Kousha. All authors approved the final version of the manuscript, Extemporanous form of midazolam was prepared by Dr Baniasadi, and Dr Salamzadeh was the consultant of study.</p></fn><fn fn-type="supported-by" id="afn2"><p><bold>Funding/Support:</bold>This work was supported by a grant from the research committee of Guilan University of Medical Sciences (GUMS), Rasht, Iran) Grant number 3910354611, register number IRCT20130203186I N4).</p></fn></fn-group><ref-list><ref id="A494REF1"><label>1</label><element-citation publication-type="book"><chapter-title>Pain, pain control and sedation.</chapter-title><person-group person-group-type="author"><name><surname>Raadal</surname><given-names>M</given-names></name><name><surname>Lundeberg</surname><given-names>S</given-names></name><name><surname>Haukali</surname><given-names>G</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Koch</surname><given-names>G</given-names></name><name><surname>Poulsen</surname><given-names>S</given-names></name></person-group><source>Pediatric Dentistry, A Clinical Approach.</source><edition>2 ed</edition><year>2009</year><fpage>54</fpage><publisher-loc>Singapore</publisher-loc><publisher-name>Blackwell</publisher-name></element-citation></ref><ref id="A494REF2"><label>2</label><element-citation publication-type="book"><chapter-title>Pain Reaction Control: Sedation.</chapter-title><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>S</given-names></name><name><surname>Ganzberg</surname><given-names>L</given-names></name></person-group><source>Pediatric Dentistry, Infancy through Adolescence.</source><edition>5 ed</edition><year>2013</year><fpage>98</fpage><publisher-loc>China</publisher-loc><publisher-name> Elsevier</publisher-name></element-citation></ref><ref id="A494REF3"><label>3</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>McDonald</surname><given-names>R</given-names></name><name><surname>Avery</surname><given-names>D</given-names></name></person-group><source>Dentistry for the child and adolescent.</source><edition>9 ed</edition><year>2013</year><publisher-loc>,China</publisher-loc><publisher-name>Mosby-Elsivier</publisher-name></element-citation></ref><ref id="A494REF4"><label>4</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Malamed</surname><given-names>S</given-names></name></person-group><source>Oral Sedation.</source><edition>5 ed</edition><year>2010</year><pub-id pub-id-type="doi">10.1016/b978-0-323-05680-9.00009-6</pub-id><publisher-loc>California</publisher-loc><publisher-name> Mosbey Elsevier</publisher-name></element-citation></ref><ref id="A494REF5"><label>5</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Reed</surname><given-names>MD</given-names></name><name><surname>Rodarte</surname><given-names>A</given-names></name><name><surname>Blumer</surname><given-names>JL</given-names></name><name><surname>Khoo</surname><given-names>KC</given-names></name><name><surname>Akbari</surname><given-names>B</given-names></name><name><surname>Pou</surname><given-names>S</given-names></name><etal>et al.</etal></person-group><article-title>The single-dose pharmacokinetics of midazolam and its primary metabolite in pediatric patients after oral and intravenous administration.</article-title><source>J Clin Pharmacol.</source><year>2001</year><volume>41</volume><issue>12</issue><fpage>1359</fpage><lpage>69</lpage><pub-id pub-id-type="pmid">11762564</pub-id></element-citation></ref><ref id="A494REF6"><label>6</label><element-citation publication-type="book"><chapter-title>Intravenous and intramuscular sedation.</chapter-title><person-group person-group-type="author"><name><surname>Becker</surname><given-names>DE</given-names></name><name><surname>Bennett</surname><given-names>CR</given-names></name></person-group><person-group person-group-type="editor"><name><surname>Dionne</surname><given-names>RA</given-names></name><name><surname>Phero</surname><given-names>JC</given-names></name><name><surname>Becker</surname><given-names>DE</given-names></name></person-group><source>Management of pain and anxiety in the dental office.</source><edition>1 ed</edition><year>2002</year><fpage>235</fpage><lpage>60</lpage><publisher-loc>United States</publisher-loc><publisher-name>Saunders</publisher-name></element-citation></ref><ref id="A494REF7"><label>7</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Alzahrani</surname><given-names>AM</given-names></name><name><surname>Amjad</surname><given-names>W</given-names></name></person-group><article-title>Use of oral midazolamsedation in pediatric dentistry; A review.</article-title><source>Pakistan Oral &#x00026; Dental J.</source><year>2012</year><volume>32</volume><issue>3</issue></element-citation></ref><ref id="A494REF8"><label>8</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Sheta</surname><given-names>SA</given-names></name><name><surname>Alsarheed</surname><given-names>M</given-names></name></person-group><article-title>Oral midazolam premedication for children undergoing general anaesthesia for dental care.</article-title><source>Int J Pediatr.</source><year>2009</year><volume>2009</volume><fpage>274380</fpage><pub-id pub-id-type="doi">10.1155/2009/274380</pub-id><pub-id pub-id-type="pmid">19946418</pub-id></element-citation></ref><ref id="A494REF9"><label>9</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Rosenberg</surname><given-names>M</given-names></name></person-group><article-title>Oral midazolam syrup as a safe sedative for pediatric dentistry.</article-title><source>Dental News.</source><year>2000</year><volume>7</volume><issue>3</issue><fpage>69</fpage><lpage>71</lpage></element-citation></ref><ref id="A494REF10"><label>10</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Goho</surname><given-names>C</given-names></name></person-group><article-title>Oral midazolam-grapefruit juice drug interaction.</article-title><source>Pediatr Dent.</source><year>2001</year><volume>23</volume><issue>4</issue><fpage>365</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">11572503</pub-id></element-citation></ref><ref id="A494REF11"><label>11</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Isik</surname><given-names>B</given-names></name><name><surname>Baygin</surname><given-names>O</given-names></name><name><surname>Bodur</surname><given-names>H</given-names></name></person-group><article-title>Effect of drinks that are added as flavoring in oral midazolam premedication on sedation success.</article-title><source>Paediatr Anaesth.</source><year>2008</year><volume>18</volume><issue>6</issue><fpage>494</fpage><lpage>500</lpage><pub-id pub-id-type="doi">10.1111/j.1460-9592.2008.02462.x</pub-id><pub-id pub-id-type="pmid">18318696</pub-id></element-citation></ref><ref id="A494REF12"><label>12</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Isik</surname><given-names>B</given-names></name><name><surname>Baygin</surname><given-names>O</given-names></name><name><surname>Kapci</surname><given-names>EG</given-names></name><name><surname>Bodur</surname><given-names>H</given-names></name></person-group><article-title>The effects of temperament and behaviour problems on sedation failure in anxious children after midazolam premedication.</article-title><source>Eur J Anaesthesiol.</source><year>2010</year><volume>27</volume><issue>4</issue><fpage>336</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1097/EJA.0b013e32833111b2</pub-id><pub-id pub-id-type="pmid">19923993</pub-id></element-citation></ref><ref id="A494REF13"><label>13</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Finley</surname><given-names>GA</given-names></name><name><surname>Stewart</surname><given-names>SH</given-names></name><name><surname>Buffett-Jerrott</surname><given-names>S</given-names></name><name><surname>Wright</surname><given-names>KD</given-names></name><name><surname>Millington</surname><given-names>D</given-names></name></person-group><article-title>High levels of impulsivity may contraindicate midazolam premedication in children.</article-title><source>Can J Anaesth.</source><year>2006</year><volume>53</volume><issue>1</issue><fpage>73</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">16371612</pub-id></element-citation></ref><ref id="A494REF14"><label>14</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Kain</surname><given-names>ZN</given-names></name><name><surname>MacLaren</surname><given-names>J</given-names></name><name><surname>McClain</surname><given-names>BC</given-names></name><name><surname>Saadat</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>SM</given-names></name><name><surname>Mayes</surname><given-names>LC</given-names></name><etal>et al.</etal></person-group><article-title>Effects of age and emotionality on the effectiveness of midazolam administered preoperatively to children.</article-title><source>Anesthesiology.</source><year>2007</year><volume>107</volume><issue>4</issue><fpage>545</fpage><lpage>52</lpage><pub-id pub-id-type="doi">10.1097/01.anes.0000281895.81168.c3</pub-id><pub-id pub-id-type="pmid">17893449</pub-id></element-citation></ref><ref id="A494REF15"><label>15</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Steedman</surname><given-names>SL</given-names></name><name><surname>Koonce</surname><given-names>JR</given-names></name><name><surname>Wynn</surname><given-names>JE</given-names></name><name><surname>Brahen</surname><given-names>NH</given-names></name></person-group><article-title>Stability of midazolam hydrochloride in a flavored, dye-free oral solution.</article-title><source>Am J Hosp Pharm.</source><year>1992</year><volume>49</volume><issue>3</issue><fpage>615</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">1598938</pub-id></element-citation></ref><ref id="A494REF16"><label>16</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Saarnivaara</surname><given-names>L</given-names></name><name><surname>Lindgren</surname><given-names>L</given-names></name><name><surname>Klemola</surname><given-names>UM</given-names></name></person-group><article-title>Comparison of chloral hydrate and midazolam by mouth as premedicants in children undergoing otolaryngological surgery.</article-title><source>Br J Anaesth.</source><year>1988</year><volume>61</volume><issue>4</issue><fpage>390</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">3190970</pub-id></element-citation></ref><ref id="A494REF17"><label>17</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Houpt</surname><given-names>MI</given-names></name><name><surname>Kupietzky</surname><given-names>A</given-names></name><name><surname>Tofsky</surname><given-names>NS</given-names></name><name><surname>Koenigsberg</surname><given-names>SR</given-names></name></person-group><article-title>Effects of nitrous oxide on diazepam sedation of young children.</article-title><source>Pediatr Dent.</source><year>1996</year><volume>18</volume><issue>3</issue><fpage>236</fpage><lpage>41</lpage><pub-id pub-id-type="pmid">8784916</pub-id></element-citation></ref><ref id="A494REF18"><label>18</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>WL</given-names></name><name><surname>Fields</surname><given-names>HW</given-names></name><name><surname>Machen</surname><given-names>JB</given-names></name></person-group><article-title>Measuring selected disruptive behaviors of the 36- to 60-month-old patient. Part I: Development and assessment of a rating scale.</article-title><source>Pediatr Dent.</source><year>1981</year><volume>3</volume><issue>3</issue><fpage>251</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">6951151</pub-id></element-citation></ref><ref id="A494REF19"><label>19</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Sheroan</surname><given-names>MM</given-names></name><name><surname>Dilley</surname><given-names>DC</given-names></name><name><surname>Lucas</surname><given-names>WJ</given-names></name><name><surname>Vann</surname><given-names>WF</given-names></name></person-group><article-title>A prospective study of 2 sedation regimens in children: chloral hydrate, meperidine, and hydroxyzine versus midazolam, meperidine, and hydroxyzine.</article-title><source>Anesth Prog.</source><year>2006</year><volume>53</volume><issue>3</issue><fpage>83</fpage><lpage>90</lpage><pub-id pub-id-type="doi">10.2344/0003-3006(2006)53[83:APSOSR]2.0.CO;2</pub-id><pub-id pub-id-type="pmid">17175821</pub-id></element-citation></ref><ref id="A494REF20"><label>20</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Tehranidoost</surname><given-names>M</given-names></name><name><surname>Shahrivar</surname><given-names>R</given-names></name></person-group><article-title> Reliability of Persian version of SDQ.</article-title><source> Tazehaye Oloum Shenakhti .</source><year>1996</year><volume>4</volume><fpage>33</fpage><lpage>9</lpage></element-citation></ref><ref id="A494REF21"><label>21</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Qasempour</surname><given-names>M</given-names></name><name><surname>Hadji-Ahmadi</surname><given-names>M</given-names></name><name><surname>Pouryiaye Vali</surname><given-names>M</given-names></name></person-group><article-title>[Dental stress in children].</article-title><source>J Babol Uni Med Sci.</source><year>1994</year><volume>3</volume><fpage>12</fpage><lpage>6</lpage></element-citation></ref><ref id="A494REF22"><label>22</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Brosius</surname><given-names>KK</given-names></name><name><surname>Bannister</surname><given-names>CF</given-names></name></person-group><article-title>Midazolam premedication in children: a comparison of two oral dosage formulations on sedation score and plasma midazolam levels.</article-title><source>Anesth Analg.</source><year>2003</year><volume>96</volume><issue>2</issue><fpage>392</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">12538183</pub-id></element-citation></ref><ref id="A494REF23"><label>23</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Cote</surname><given-names>CJ</given-names></name><name><surname>Cohen</surname><given-names>IT</given-names></name><name><surname>Suresh</surname><given-names>S</given-names></name><name><surname>Rabb</surname><given-names>M</given-names></name><name><surname>Rose</surname><given-names>JB</given-names></name><name><surname>Weldon</surname><given-names>BC</given-names></name><etal>et al.</etal></person-group><article-title>A comparison of three doses of a commercially prepared oral midazolam syrup in children.</article-title><source>Anesth Analg.</source><year>2002</year><volume>94</volume><issue>1</issue><fpage>37</fpage><lpage>43</lpage><pub-id pub-id-type="pmid">11772797</pub-id></element-citation></ref><ref id="A494REF24"><label>24</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Somri</surname><given-names>M</given-names></name><name><surname>Parisinos</surname><given-names>CA</given-names></name><name><surname>Kharouba</surname><given-names>J</given-names></name><name><surname>Cherni</surname><given-names>N</given-names></name><name><surname>Smidt</surname><given-names>A</given-names></name><name><surname>Abu Ras</surname><given-names>Z</given-names></name><etal>et al.</etal></person-group><article-title>Optimising the dose of oral midazolam sedation for dental procedures in children: a prospective, randomised, and controlled study.</article-title><source>Int J Paediatr Dent.</source><year>2012</year><volume>22</volume><issue>4</issue><fpage>271</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1111/j.1365-263X.2011.01192.x</pub-id><pub-id pub-id-type="pmid">22040450</pub-id></element-citation></ref><ref id="A494REF25"><label>25</label><element-citation publication-type="journal" publication-format="print"><person-group person-group-type="author"><name><surname>Mortazavi</surname><given-names>M</given-names></name><name><surname>Pourhashemi</surname><given-names>SJ</given-names></name><name><surname>Khosravi</surname><given-names>MB</given-names></name><name><surname>Ashtari</surname><given-names>S</given-names></name><name><surname>Ghaderi</surname><given-names>F</given-names></name></person-group><article-title>Assessment of a low dose of IV midazolam used orally for conscious sedation in pediatric dentistry.</article-title><source>DARU Journal of Pharmaceutical Sciences.</source><year>2009</year><volume>17</volume><issue>2</issue><fpage>79</fpage><lpage>82</lpage></element-citation></ref><ref id="A494REF26"><label>26</label><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Jew</surname><given-names>R</given-names></name><name><surname>Soo-Hoo</surname><given-names>W</given-names></name><name><surname>Erush</surname><given-names>S</given-names></name></person-group><source>Extemporaneous formulations for pediatric, geriatric, and special needs patients.</source><year>2010</year><isbn>1585282456</isbn><publisher-loc>America</publisher-loc><publisher-name>American Society of Health-System Pharmacists</publisher-name></element-citation></ref></ref-list></back></article>